Drug Profile
Alzheimer's nasal spray - Emphycorp
Latest Information Update: 28 Feb 2018
Price :
$50
*
At a glance
- Originator Emphycorp
- Class Antidementias
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for phase-I development in Alzheimer's-disease in USA (Intranasal, Spray)
- 10 Mar 2016 Emphycorp plans a clinical trial for Alzheimer's disease in USA